5, 6 However, no disease-specific therapy exists to improve prognosis in this heterogeneous syndrome, despite multiple randomized controlled trials.
1, 2 HFpEF is associated with rates of HF re-hospitalization and functional decline similar to HF with reduced EF (HFrEF), 3, 4 and carries a significantly higher risk of death compared to age-matched controls. More detailed assessment of cardiac structure and function in broader HFpEF populations will be necessary to better define the prevalence, determinants, and prognostic relevance of these measures, which may in turn serve as a foundation to identify pathophysiologically relevant sub-phenotypes within this diverse syndrome.ĭata from community-based studies have established that heart failure with preserved ejection fraction (HFpEF) accounts for up to 50% of HF cases and is increasing in prevalence.
#Shaw bijou failed trial#
A review of larger imaging studies from epidemiology and clinical trial cohorts demonstrate that while concentric LV remodeling is common, it is by no means universal and many patients demonstrate normal LV geometry or even an eccentric pattern. However, marked clinical heterogeneity within this syndrome is now well appreciated, and is mirrored in the variability in left ventricular structure. HFpEF has commonly been viewed as an expression of advanced hypertensive heart disease, with a cardiac phenotype characterized by an increase in wall thickness-to-chamber radius ratio (concentric hypertrophy). Heart failure with preserved ejection fraction (HFpEF) is common, increasing in prevalence, and causes substantial morbidity and mortality.
0 kommentar(er)
